Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CARM1 | Q86X55 | 2/20 | 0.61 |
| ▸ | PRMT5 | O14744 | 13/20 | 0.56 |
| ▸ | WDR77 | Q9BQA1 | 10/20 | 0.56 |
| ▸ | LMNA | P02545 | 1/20 | 0.52 |
| ▸ | HTT | P42858 | 1/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30304699 | 0.85 | CARM1 (0.66) | CARM1PRMT5WDR77LMNAHTT | |
| SCHEMBL28057271 | 0.85 | CARM1 (0.66) | CARM1PRMT5WDR77LMNAHTT | |
| SCHEMBL26224409 | 0.85 | CARM1 (0.66) | CARM1PRMT5WDR77LMNAHTT | |
| SCHEMBL18212446 | 0.85 | CARM1 (0.57) | CARM1PRMT5WDR77LMNAHTT | |
| SCHEMBL28057284 | 0.85 | CARM1 (0.66) | CARM1PRMT5WDR77LMNAHTT | |
| SCHEMBL28655189 | 0.85 | CARM1 (0.57) | CARM1PRMT5WDR77LMNAHTT | |
| Hydrochloric Acid SCHEMBL18205181 | 0.84 | CARM1 (0.56) | CARM1PRMT5WDR77LMNAHTT | |
| Hydrochloric Acid SCHEMBL18205182 | 0.84 | CARM1 (0.56) | CARM1PRMT5WDR77LMNAHTT | |
| SCHEMBL3418321 | 0.82 | CARM1 (0.60) | CARM1PRMT5WDR77LMNAHTT | |
| SCHEMBL30019323 | 0.82 | CARM1 (0.74) | CARM1PRMT5WDR77LMNAHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230365558-A1 | TETRAHYDROISOQUINOLINE DERIVATIVE AND USE THEREOF | MEDSHINE DISCOVERY INC. (CN) | 2023-11-16 | — | — | US | disclosed |
| US-20230365558-A1 | TETRAHYDROISOQUINOLINE DERIVATIVE AND USE THEREOF | MEDSHINE DISCOVERY INC. (CN) | 2023-11-16 | — | — | US | disclosed |
| EP-4219461-A1 | TETRAHYDROISOQUINOLINE DERIVATIVE AND USE THEREOF | Medshine Discovery Inc. (CN) | 2023-08-02 | — | — | EP | disclosed |
| WO-2022063094-A1 | TETRAHYDROISOQUINOLINE DERIVATIVE AND USE THEREOF | 南京明德新药研发有限公司 | 2022-03-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230365558-A1 | TETRAHYDROISOQUINOLINE DERIVATIVE AND USE THEREOF | CYP3A7, UGT2B7, SFPQ | CARM1 2581/4885PRMT5 624/4885WDR77 1918/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.